White Knight Strategic Wealth Advisors LLC Acquires New Shares in Edwards Lifesciences Co. (NYSE:EW)

White Knight Strategic Wealth Advisors LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,098 shares of the medical research company's stock, valued at approximately $303,000.

A number of other institutional investors have also recently made changes to their positions in EW. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $610,895,000. Jennison Associates LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $555,939,000. Vanguard Group Inc. lifted its position in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Raymond James Financial Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $213,844,000. Finally, Marshall Wace LLP lifted its position in Edwards Lifesciences by 55.7% during the 4th quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock worth $430,367,000 after acquiring an additional 2,079,642 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and an average price target of $80.20.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This trade represents a 1.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,150,791.86. This represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,692 shares of company stock valued at $4,822,074. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.19 during trading on Friday, reaching $74.98. The company had a trading volume of 3,738,140 shares, compared to its average volume of 5,138,901. The firm has a market capitalization of $43.98 billion, a PE ratio of 10.76, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The firm's 50-day simple moving average is $72.78 and its 200 day simple moving average is $72.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.66 earnings per share. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.